Toxicodendron dermatitis (TD) is a common form of allergic contact dermatitis that affects millions of Americans every year. Studies have shown that although there are general recommendations for the treatment of TD, there are no treatment algorithms for clinicians to follow when patients present with TD.
Objective
The objective of this study was to achieve consensus on the treatment of TD to create practical guidelines for physicians who treat TD.
Methods
Data were collected from March 2020 to April 2021. This study included semistructured focus groups and a Delphi Study with dermatologists to achieve consensus.
Results
A total of 51 dermatologists were included in the Delphi. Final agreement with proposed severity criteria ranged from 90.9% to 100.0%. Primary indicators of disease severity were body surface area, presence and severity of pruritus, and anatomic locations of eruptions with 77.4% agreement. Final agreement for the treatment algorithm was over the threshold majority agreement at 67.6%.
Conclusions
Literature guiding the treatment of TD is scarce. The use of the Delphi method and focus groups can help expand dermatological resources both within dermatology and to other specialties that may need to treat skin conditions.
Get full access to this article
View all access options for this article.
References
1.
KimY, FlammA, ElSohlyMA, et al. Poison ivy, oak, and sumac dermatitis: what is known and what is new?Dermatitis 2019;30(3):183–190. doi:.
ZomorodiN, ButtM, MaczugaS, MarksJ, FlammA. Cost and diagnostic characteristics of Toxicodendron dermatitis in the USA: a retrospective cross-sectional analysis. Br J Dermato, 2020; 183(4):772–773. doi:.
4.
GuinJD. Treatment of Toxicodendron dermatitis (poison ivy and poison oak). Skin Therapy Lett, 2001; 6(7):3–5.
5.
FisherAA. Treatment of Rhus dermatitis with non-prescription products. J Am Med Womens Assoc (1972), 1972; 27(9):482–485.
6.
VaughtCK, MoldJW. Poison ivy: how effective are available treatments?J Fam Pract 2016;65(11):801–809.
7.
BoelmanDJ. Emergency: treating poison ivy, oak, and sumac. Am J Nurs, 2010; 110(6):49–52. doi:.
8.
Treating poisonous plants' rash of symptoms. Harv Womens Health Watch 2003;10(12):6–7.
9.
GoodallJ. Oral corticosteroids for poison ivy dermatitis. CMAJ, 2002; 166(3):300–301.
10.
SternbachG, CallenJP. Dermatitis. Emerg Med Clin North Am, 1985; 3(4):677–692.
11.
BrodellRT, WilliamsL. Taking the itch out of poison ivy. Are you prescribing the right medication?Postgrad Med, 1999; 106(1):69–70. doi:.
12.
GuayDR. An update on plant-related contact dermatitis. J Pract Nurs, 1993; 43(4):24–31.
13.
McGuffeyEC. What methods are effective to prevent or treat poison ivy/oak/sumac?Am Pharm 1993;NS33(5):18.
14.
BriantD, BrouderG. Identification and treatment of poison ivy dermatitis. Nurse Pract, 1983; 8(7):13, 16, 19 passim.
15.
GladmanAC. Toxicodendron dermatitis: poison ivy, oak, and sumac. Wilderness Environ Med, 2006; 17(2):120–128.
ResnickSD. Poison-ivy and poison-oak dermatitis. Clin Dermatol, 1986; 4(2):208–12. doi:.
18.
CraigK, MeadowsSE. What is the best duration of steroid therapy for contact dermatitis (Rhus)?J Fam Pract 2006;55(2):166–167; discussion 166.
19.
LeeNP, ArriolaER. Poison ivy, oak, and sumac dermatitis. West J Med, 1999; 171(5–6):354–355.
20.
CurtisG, LewisAC. Treatment of severe poison ivy: a randomized, controlled trial of long versus short course oral prednisone. J Clin Med Res, 2014; 6(6):429–434. doi:.
WooldridgeWE. Acute allergic contact dermatitis. How to manage severe cases. Postgrad Med, 1990; 87(4):221–4. doi:.
23.
SlaughterRJ, BeasleyMG, SchepLJ. Dermatitis due to Toxicodendron plants: a common occurrence during autumn. N Z Med J, 2017; 130(1451):82–83.
24.
ZaengleinAL, LevyML, StefankoNS, et al.Consensus recommendations for the use of retinoids in ichthyosis and other disorders of cornification in children and adolescents. Pediatr Dermatol, 2021; 38(1):164–180. doi:.
25.
GelfandJM, ArmstrongAW, BellS, et al.National Psoriasis Foundation COVID-19 Task Force guidance for management of psoriatic disease during the pandemic: version 2—advances in psoriatic disease management, COVID-19 vaccines, and COVID-19 treatments. J Am Acad Dermatol, 2021; 84(5):1254–1268. doi:.
26.
De Bruin-WellerM, BiedermannT, BissonnetteR, et al.Treat-to-target in atopic dermatitis: an international consensus on a set of core decision points for systemic therapies. Acta Derm Venereol. 2021; 101(2):adv00402. doi:.
27.
HanifinJM, ThurstonM, OmotoM, CherillR, TofteSJ, GraeberM. The Eczema Area and Severity Index (EASI): assessment of reliability in atopic dermatitis. EASI Evaluator Group. Exp Dermatol, 2001; 10(1):11–8. doi:.
28.
GoldfarbN, LowesMA, ButtM, KingT, AlaviA, KirbyJS. Hidradenitis Suppurativa Area and Severity Index Revised (HASI-R): psychometric property assessment. Br J Dermatol 2021, 184, 905–912;doi:.
29.
PuzenatE, BronsardV, PreyS, et al.What are the best outcome measures for assessing plaque psoriasis severity? A systematic review of the literature. J Eur Acad Dermatol Venereol, 2010; 24suppl 2:10–6. doi:.
30.
CharmanC, WilliamsH. Outcome measures of disease severity in atopic eczema. Arch Dermatol, 2000; 136(6):763–9. doi:.
31.
FinlayAY, KhanGK. Dermatology Life Quality Index (DLQI)—a simple practical measure for routine clinical use. Clin Exp Dermatol, 1994; 19(3):210–216.
32.
ChrenMM, LasekRJ, FlockeSA, et al.Improved discriminative and evaluative capability of a refined version of Skindex, a quality-of-life instrument for patients with skin diseases. Arch Dermatol, 1997; 133(11):1433–1440.
33.
ChrenMM, LasekRJ, QuinnLM, MostowEN, ZyzanskiSJ. Skindex, a quality-of-life measure for patients with skin disease: reliability, validity, and responsiveness. J Invest Dermatol, 1996; 107(5):707–13. doi:.
34.
ChrenMM, LasekRJ, SahayAP, SandsLP. Measurement properties of Skindex-16: a brief quality-of-life measure for patients with skin diseases. J Cutan Med Surg, 2001; 5(2):105–10. doi:.
35.
GirmanCJ, HartmaierS, ThiboutotD, et al.Evaluating health-related quality of life in patients with facial acne: development of a self-administered questionnaire for clinical trials. Qual Life Res, 1996; 5(5):481–90. doi:.
36.
MartinAR, LookingbillDP, BotekA, LightJ, ThiboutotD, GirmanCJ. Health-related quality of life among patients with facial acne—assessment of a new acne-specific questionnaire. Clin Exp Dermatol, 2001; 26():380–5. doi:.
37.
KirbyJS, ThorlaciusL, VillumsenB, et al. The Hidradenitis Suppurativa Quality of Life (HiSQOL) score: development and validation of a measure for clinical trials. Br J Dermatol 2020, 183, 340–348;doi:.
38.
CharmanCR, VennAJ, WilliamsHC. The patient-oriented eczema measure: development and initial validation of a new tool for measuring atopic eczema severity from the patients' perspective. Arch Dermatol, 2004; 140(12):1513–9. doi:.
39.
BushnellDM, MartinML, McCarrierK, et al.Validation of the Psoriasis Symptom Inventory (PSI), a patient-reported outcome measure to assess psoriasis symptom severity. J Dermatolog Treat, 2013; 24(5):356–60. doi:.
40.
IvesTJ, TepperRS. Failure of a tapering dose of oral methylprednisolone to treat reactions to poison ivy. JAMA, 1991; 266(10):1362.
41.
DoumourasAG, LeeY, BabeG, et al.The hidden cost of an extensive preoperative work-up: predictors of attrition after referral for bariatric surgery in a universal healthcare system. Surg Endosc, 2020; 34(2):988–995. doi:.
42.
Poison ivy. Nursing 2014;44(6):47. doi:.
43.
SaaryJ, QureshiR, PaldaV, et al.A systematic review of contact dermatitis treatment and prevention. J Am Acad Dermatol, 2005; 53(5):845. doi:.
